Immunoexpression of Nestin and Ki-67 in Astrocytoma in a Single Tertiary Health Care Centre
Abstract
OBJECTIVE: To evaluate the prognostic significance of Nestin and Ki-67 expression in Astrocytoma across different grades.
METHODOLOGY: A retrospective cross-sectional analysis was conducted at the Histology Department, Basic Medical Sciences Institute, JPMC Karachi, between October 2019 and September 2022. In this study, Nestin and KI-67 immunohistochemistry expression was assessed in 60 Astrocytoma, and its expression was seen with different degrees of Astrocytoma.
RESULTS: Nestin positivity was found in 86.7% of cases of Astrocytoma. The immune-reactive score for Nestin staining in different stages of Astrocytoma was shown to have a significantly significant P-value. 41.7% of cases of Astrocytoma were found to have a KI-67 labeling index; all high-grade Astrocytoma had a high labeling index of Ki-67. It was demonstrated that the immune-reactive score for Ki-67 staining at various phases of Astrocytoma had a statistically significant P-value.
CONCLUSION: We discovered that Nestin and Ki-67 were expressed in Astrocytoma and that the expression of both immune markers rose with tumor grade. Nestin and Ki-67 serve as a helpful marker for assessing the Astrocytoma's prognosis. These findings may be used to determine the best course of action for Astrocytoma therapy.
References
Salari N, Ghasemi H, Fatahian R, Mansouri K, Dokaneheifard S, Shiri MH et al. The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis. Eur J Med Res. 2023; 28(1): 39. doi: 10.1186/s40001-023-01011-y.
Mirchia K, Sathe AA, Walker JM, Fudym Y, Galbraith K, Viapiano MS et al. Total copy number variation as a prognostic factor in adult astrocytoma subtypes. Acta Neuropatholog Commun. 2019; 7: 8. doi: 10.1186/s40478-019-0746-y.
Mahmood S, Faraz R, Yousaf A, Quader A, Asif H, Atif A et al. Annual Cancer Registry Report 2017 of the Shaukat Khanum Memorial Cancer Hospital & Research Center, Pakistan. Shoukat Khanam Memorial Cancer Hospital Research Centre. 2018. Available from: https://shaukatkhanum.org.pk/wp-content/uploads/2018/08/acrr-2017.pdf.
Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021; 71(5): 381-406. doi: 10.3322/caac.21693. Epub 2021 Aug 24.
Hirtz A, Rech F, Dubois-Pot-Schneider H, Dumond H. Astrocytoma: a hormone-sensitive tumor? Int J Mol Sci. 2020; 21(23): 9114. doi: 10.3390/ijms21239114.
Yang W, Warrington NM, Taylor SJ, Whitmire P, Carrasco E, Singleton KW et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Translat Med. 2019; 11(473): eaao5253. doi: 10.1126/scitranslmed.aao5253.
Kapoor M, Gupta V. Astrocytoma. In: StatPearls [Internet]. StatPearls Publishing; 2021. Medicine, MacDonald T, Packer RJ. Pediatric Astrocytoma.
Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci. 2015; 106(7): 803-11. doi: 10.1111/cas.12691. Epub 2015 May 26.
Bernal A, Arranz L. Nestin-expressing progenitor cells: function, identity and therapeutic implications. Cell Mol Life Sci. 2018; 75(12): 2177-95. doi: 10.1007/s00018-018-2794-z. Epub 2018 Mar 14.
Yamagishi A, Susaki M, Takano Y, Mizusawa M, Mishima M, Iijima M et al. The structural function of Nestin in cell body softening is correlated with cancer cell metastasis. Int J Biol Sci. 2019; 15(7): 1546-56. doi: 10.7150/ijbs.33423.
Andrés-Sánchez N, Fisher D, Krasinska L. Physiological functions and roles in cancer of the proliferation marker Ki-67. J Cell Sci. 2022; 135(11): jcs258932. doi: 10.1242/jcs.258932. Epub 2022 Jun 8.
Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG et al. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. 2016; 7(5): 6281-93. doi: 10.18632/oncotarget.7057.
Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019; 491: 39-45. doi: 10.1016/j.cca.2019.01.011.
Abdelkareem RM, Elnashar AT, Fadle KN, Muhammad EM. Immunohistochemical expression of Nestin as cancer stem cell marker in gliomas. J Neurol Neurol Disord. 2019; 5(1): 047-051. doi: 10.17352/jnnsd.000033.
Bolly HM, Faried A, Hermanto Y, Lubis BP, Tjahjono FP, Hernowo BS et al. Analysis of mutant isocitrate dehydrogenase 1 immunoexpression, Ki-67 and programmed death ligand 1 in diffuse astrocytic tumours: study of single center in Bandung, Indonesia. J Korean Neurosurg Soc. 2021; 64(1): 100-109. doi: 10.3340/jkns.2020.0071.
Woo CG. Clinicopathological Significance of Nestin Expression as a Diagnostic and Prognostic Marker in Brain Gliomas, Independent of IDH Mutation. Research Square. 2021; 1-10. doi: 10.21203/re.3.re-994741/v1.
An S, Song IH, Woo CG. Diagnostic Value of Nestin Expression in Adult Gliomas. Int J Surg Pathol. 2023; 31(6): 1014-20. doi: 10.1177/10668969221125792. Epub 2022 Sep 27.
Rehfeld M, Matschke J, Hagel C, Willenborg K, Glatzel M, Bernreuther C. Differential expression of stem cell markers in proliferating cells in glioma. J Cancer Res Clin Oncol. 2021; 147(10): 2969-82. doi: 10.1007/s00432-021-03704-5.
Rushing EJ, Sandberg GD, Horkayne-Szakaly I. High-grade astrocytomas show increased Nestin and Wilms's tumor gene (WT1) protein expression. Int J Surg Pathol. 2010; 18(4): 255-9. doi: 10.1177/1066896909338596. Epub 2009 Jul 3.
Dahlrot RH, Hansen S, Schroeder HD, Jensen SS, Hjelmborg J, Kristensen BW. P04.09: The Prognostic Potential Of Cd133 And Nestin In A Population-Based Cohort Of Glioma Patients. Neuro Oncol. 2014; 16(Suppl 2): ii38. doi: 10.1093/neuonc/nou174.141.
Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM, Oliver D et al. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II–III astrocytomas and oligoastrocytomas. J Neuro Oncol. 2014; 117(1): 183-9. doi: 10.1007/s11060-014-1376-7.
Muslim LM, Hasan MM, Dosh ZN, Altoraihi KM. Immunohistochemical Study of P53 and Ki-67 in Astrocytoma. Ann Roman Soc Cell Biol. 2021: 25(1): 6507-25.
Eneström S, Vavruch L, Frånlund B, Nordenskjöld B. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neuro Chirurgie. 1998; 44(1): 25-30.
Torp SH. Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol. 2002; 21(6): 252-7.
Das B, Raj KV, Atla B. Clinicohistopathological study of astrocytomas along with Ki-67 proliferative index. Int J Res Med Sci. 2018; 6(6): 665-70.
Dahlrot RH, Bangsø JA, Petersen JK, Rosager AM, Sørensen MD, Reifenberger G et al. Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. Scientif Reports. 2021; 11(1): 1-9.
Shivaprasad NV, Satish S, Ravishankar S, Vimalambike MG. Ki-67 immunostaining in astrocytomas: Association with histopathological grade–A South Indian study. J Neurosci Rural Pract. 2016; 7(4): 510-514. doi: 10.4103/0976-3147.188626.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Liaquat University of Medical & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Submission of a manuscript to the journal implies that all authors have read and agreed to the content of the undertaking form or the Terms and Conditions.
When an article is accepted for publication, the author(s) retain the copyright and are required to grant the publisher the right of first publication and other non-exclusive publishing rights to JLUMHS.
Articles published in the Journal of Liaquat University of Medical & health sciences are open access articles under a Creative Commons Attribution-Noncommercial - Share Alike 4.0 License. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. This is in accordance with the BOAI definition of open access. In addition to that users are allowed to remix, tweak and build upon the work non-commercially as long as appropriate credit is given and the new creations are licensed under the identical terms. Or, in certain cases it can be stated that all articles and content there in are published under creative commons license unless stated otherwise.
